New drug hope for rare childhood immune disorders

NCT ID NCT07364513

Recruiting now Disease control Sponsor: ImmuneSensor Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new medicine called IMSB301 in people with rare diseases where the immune system attacks the body. The study includes up to 6 participants aged 12 and older. The main goal is to check if the drug is safe and how it behaves in the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AICARDI-GOUTIÈRES SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Aicardi-Goutieres syndrome autoimmune interstitial lung disease-arthritis syndrome autoinflammatory-pancytopenia syndrome due to DNASE2 deficiency familial chilblain lupus systemic lupus erythematosus type 1 interferonopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 INTERFERONOPATHIES

Contacts and locations

Locations

The Children's Hospital at Westmead
RECRUITING

Sydney, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.